Biotech News

Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026

Precision BioSciences (DTIL)Precision BioSciences2026-04-30 11:01 ESTEarnings

DURHAM, N.C. --(BUSINESS WIRE)--Apr. 30, 2026-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial

Precision BioSciences

ARCUS Gene Editing Platform Precision BioSciences develops in vivo gene-editing therapies using ARCUS nucleases. The compact enzymes are designed for several editing modes, including elimination of viral DNA, excision of defective genomic regions and targeted insertion of functional genetic material. PBGENE-HBV PBGENE-HBV is a wholly...

Recent company news

DTILPrecision BioSciences2026-07-31 11:01 EST

Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026

DTILPrecision BioSciences2026-07-27 11:01 EST

Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones

DTILPrecision BioSciences2026-07-10 11:01 EST

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DTILPrecision BioSciences2026-06-29 11:01 EST

Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors

DTILPrecision BioSciences2026-05-27 06:30 EST

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

Stock data

Close: 7.42 USD
Market cap: 163.07M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States